J. Hayesmoore, N. Bray, W. Cross, M. Owen, . Donovan-'mc et al., The effect of age and the H1c MAPT haplotype on MAPT expression in human brain, Neurobiology of Aging, vol.30, issue.10
DOI : 10.1016/j.neurobiolaging.2007.12.017

A. Myers, A. Pittman, A. Zhao, K. Rohrer, M. Kaleem et al., The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts, Neurobiology of Disease, vol.25, issue.3, pp.561-570, 2007.
DOI : 10.1016/j.nbd.2006.10.018

T. Caffrey, C. Joachim, S. Paracchini, M. Esiri, and R. Wade-martins, Haplotype-specific expression of exon 10 at the human MAPT locus, Human Molecular Genetics, vol.15, issue.24, pp.3529-3537, 2006.
DOI : 10.1093/hmg/ddl429

A. Llado, M. Ezquerra, C. Gaig, R. Sanchez-valle, E. Tolosa et al., Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients, Journal of Neural Transmission, vol.59, issue.12, pp.1585-1588, 2007.
DOI : 10.1007/s00702-007-0786-5

A. Goris, C. Williams-gray, G. Clark, T. Foltynie, S. Lewis et al., Tau and ??-synuclein in susceptibility to, and dementia in, Parkinson's disease, Annals of Neurology, vol.300, issue.2, pp.145-153, 2007.
DOI : 10.1002/ana.21192

G. Meola and S. V. , Cerebral involvement in myotonic dystrophies, Muscle & Nerve, vol.9, issue.3, pp.294-306, 2007.
DOI : 10.1002/mus.20800

V. Sansone, S. Gandossini, M. Cotelli, M. Calabria, O. Zanetti et al., Cognitive impairment in adult myotonic dystrophies: a longitudinal study, Neurological Sciences, vol.28, issue.1, pp.9-15, 2007.
DOI : 10.1007/s10072-007-0742-z

L. Ranum and T. Cooper, RNA-mediated neuromuscular disorders . Annual review of neuroscience, pp.259-277, 2006.
DOI : 10.1146/annurev.neuro.29.051605.113014

P. Vermersch, N. Sergeant, M. Ruchoux, H. Hofmann-radvanyi, A. Wattez et al., Specific tau variants in the brains of patients with myotonic dystrophy, Neurology, vol.47, issue.3, pp.711-717, 1996.
DOI : 10.1212/WNL.47.3.711

N. Kuyumcu-martinez and T. Cooper, Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy . Progress in molecular and subcellular biology, pp.133-159, 2006.

H. Jiang, A. Mankodi, M. Swanson, R. Moxley, and C. Thornton, Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons, Human Molecular Genetics, vol.13, issue.24, pp.3079-3088, 2004.
DOI : 10.1093/hmg/ddh327

N. Sergeant, B. Sablonniere, S. Schraen-maschke, A. Ghestem, C. Maurage et al., Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1, Human Molecular Genetics, vol.10, issue.19, pp.2143-2155, 2001.
DOI : 10.1093/hmg/10.19.2143

C. Maurage, B. Udd, M. Ruchoux, P. Vermersch, H. Kalimo et al., Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease, Neurology, vol.65, issue.10, pp.1636-1638, 2005.
DOI : 10.1212/01.wnl.0000184585.93864.4e

C. Dhaenens, S. Schraen-maschke, H. Tran, V. Vingtdeux, D. Ghanem et al., Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats, Experimental Neurology, vol.210, issue.2, pp.467-478, 2008.
DOI : 10.1016/j.expneurol.2007.11.020

URL : https://hal.archives-ouvertes.fr/hal-00282892

D. Cho and S. Tapscott, Myotonic dystrophy: Emerging mechanisms for DM1 and DM2, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1772, issue.2, pp.195-204, 2007.
DOI : 10.1016/j.bbadis.2006.05.013

URL : https://hal.archives-ouvertes.fr/hal-00562719

P. Delobel, C. Mailliot, M. Hamdane, A. Sambo, S. Begard et al., Stable-Tau Overexpression in Human Neuroblastoma Cells, Annals of the New York Academy of Sciences, vol.412, issue.1, pp.623-634, 2003.
DOI : 10.1196/annals.1299.115

M. Higuchi, T. Ishihara, B. Zhang, M. Hong, A. Andreadis et al., Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration, Neuron, vol.35, issue.3, pp.433-446, 2002.
DOI : 10.1016/S0896-6273(02)00789-4

M. Ingelsson, K. Ramasamy, C. Russ, S. Freeman, J. Orne et al., Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains, Acta Neuropathologica, vol.49, issue.5, pp.471-479, 2007.
DOI : 10.1007/s00401-007-0280-z

T. Ohkubo, Y. Sakasegawa, H. Toda, H. Kishida, K. Arima et al., Three-repeat Tau 69 is a major tau isoform in laser-microdissected Pick bodies, Amyloid, vol.100, issue.1, pp.1-5, 2006.
DOI : 10.1016/0896-6273(92)90117-V

J. Tobin, J. Latourelle, M. Lew, C. Klein, O. Suchowersky et al., Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study, Neurology, vol.71, issue.1, pp.28-34, 2008.
DOI : 10.1212/01.wnl.0000304051.01650.23

D. Glatz, D. Rujescu, Y. Tang, F. Berendt, A. Hartmann et al., The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease, Journal of Neurochemistry, vol.280, issue.3, pp.635-644, 2006.
DOI : 10.1016/S0006-8993(99)01486-9

T. Arai, K. Ikeda, H. Akiyama, K. Tsuchiya, S. Iritani et al., Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer s disease, Pick s disease, progressive supranuclear palsy and corticobasal degeneration, Acta neuropathologica, vol.105, issue.5, pp.489-498, 2003.

Y. Umeda, S. Taniguchi, K. Arima, Y. Piao, H. Takahashi et al., Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies, Neuroscience Letters, vol.359, issue.3, pp.151-154, 2004.
DOI : 10.1016/j.neulet.2004.01.060

M. Ingelsson, K. Ramasamy, I. Cantuti-castelvetri, L. Skoglund, T. Matsui et al., No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer???s disease brain, Acta Neuropathologica, vol.285, issue.4, pp.439-449, 2006.
DOI : 10.1007/s00401-006-0095-3

F. Hernandez, J. Avila, and . Tauopathies, Tauopathies, Cellular and Molecular Life Sciences, vol.64, issue.17, pp.2219-2233, 2007.
DOI : 10.1007/s00018-007-7220-x

C. Andorfer, C. Acker, Y. Kress, P. Hof, K. Duff et al., Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms, Journal of Neuroscience, vol.25, issue.22, pp.5446-5454, 2005.
DOI : 10.1523/JNEUROSCI.4637-04.2005

K. Santacruz, J. Lewis, T. Spires, J. Paulson, L. Kotilinek et al., Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function, Science, vol.309, issue.5733, pp.476-481, 2005.
DOI : 10.1126/science.1113694

H. Lee, G. Perry, P. Moreira, M. Garrett, Q. Liu et al., Tau phosphorylation in Alzheimer s disease: pathogen or protector?

M. Arrasate, S. Mitra, E. Schweitzer, M. Segal, and S. Finkbeiner, Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature, vol.19, issue.7010, pp.805-810, 2004.
DOI : 10.1016/j.nbd.2004.04.001

C. Wittmann, M. Wszolek, J. Shulman, P. Salvaterra, J. Lewis et al., Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles, Science, vol.293, issue.5530, pp.711-714, 2001.
DOI : 10.1126/science.1062382

D. Terwel, R. Lasrado, J. Snauwaert, E. Vandeweert, C. Van-haesendonck et al., Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice, Journal of Biological Chemistry, vol.280, issue.5, pp.3963-3973, 2005.
DOI : 10.1074/jbc.M409876200

S. Chen, B. Li, I. Grundke-iqbal, and K. Iqbal, I PP2A 1 Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A, Journal of Biological Chemistry, vol.283, issue.16, pp.10513-10521, 2008.
DOI : 10.1074/jbc.M709852200

J. Augustinack, A. Schneider, E. Mandelkow, and B. Hyman, Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer s disease

H. Yoshida and M. Goedert, Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38? or JNK2 in the presence of heparin generates the AT100 epitope, Journal of Neurochemistry, vol.61, issue.1, pp.154-164, 2006.
DOI : 10.1046/j.1432-1327.1998.2520542.x

A. Delacourte, Y. Robitaille, N. Sergeant, L. Buee, P. Hof et al., Specific Pathological Tau Protein Variants Characterize Pick??s Disease, Journal of Neuropathology and Experimental Neurology, vol.55, issue.2, pp.159-168, 1996.
DOI : 10.1097/00005072-199602000-00004

A. Probst, M. Tolnay, D. Langui, M. Goedert, and M. Spillantini, Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment, Acta Neuropathologica, vol.92, issue.6, pp.588-596, 1996.
DOI : 10.1007/s004010050565

L. Fasulo, G. Ugolini, M. Visintin, A. Bradbury, C. Brancolini et al., The Neuronal Microtubule-Associated Protein Tau Is a Substrate for Caspase-3 and an Effector of Apoptosis, Journal of Neurochemistry, vol.1, issue.2, pp.624-633, 2000.
DOI : 10.1046/j.1471-4159.2000.0750624.x

T. Gamblin, F. Chen, A. Zambrano, A. Abraha, S. Lagalwar et al., Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.10032-10037, 2003.
DOI : 10.1073/pnas.1630428100

L. Yang and H. Ksiezak-reding, Calpain-Induced Proteolysis of Normal Human Tau and Tau Associated with Paired Helical Filaments, European Journal of Biochemistry, vol.15, issue.1, pp.9-17, 1995.
DOI : 10.1016/0014-5793(86)80060-6

D. David, R. Layfield, L. Serpell, Y. Narain, M. Goedert et al., Proteasomal degradation of tau protein, Journal of Neurochemistry, vol.72, issue.1, pp.176-185, 2002.
DOI : 10.1046/j.1471-4159.2002.01137.x

A. Guillozet-bongaarts, M. Cahill, V. Cryns, M. Reynolds, R. Berry et al., Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo, Journal of Neurochemistry, vol.69, issue.4, pp.1005-1014, 2006.
DOI : 10.1073/pnas.96.4.1391

L. Fasulo, G. Ugolini, and A. Cattaneo, Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K, Journal of Alzheimer's Disease, vol.7, issue.1, pp.3-13, 2005.
DOI : 10.3233/JAD-2005-7102

S. Albrecht, M. Bourdeau, D. Bennett, E. Mufson, M. Bhattacharjee et al., Activation of caspase-6 in aging and mild cognitive impairment . The American journal of pathology, pp.1200-1209, 2007.

P. Delobel, O. Leroy, M. Hamdane, A. Sambo, A. Delacourte et al., Proteasome inhibition and Tau proteolysis: an unexpected regulation, FEBS Letters, vol.69, issue.1, pp.1-5, 2005.
DOI : 10.1016/j.febslet.2004.11.018

C. Cotman, W. Poon, R. Rissman, and M. Blurton-jones, The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology, Journal of Neuropathology & Experimental Neurology, vol.64, issue.2, pp.104-112, 2005.
DOI : 10.1093/jnen/64.2.104

F. Garcia-sierra, N. Ghoshal, B. Quinn, R. Berry, and L. Binder, Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease, Journal of Alzheimer's Disease, vol.5, issue.2, pp.65-77, 2003.
DOI : 10.3233/JAD-2003-5201

S. Wray, M. Saxton, B. Anderton, and D. Hanger, Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats, Journal of Neurochemistry, vol.60, issue.6, 2008.
DOI : 10.1111/j.1471-4159.2008.05321.x

A. Delacourte, N. Sergeant, and L. Buee, Neurodegenerative Diseases, p.690, 2007.
DOI : 10.1007/978-1-59745-336-3_20

D. Hanger, D. Mann, D. Neary, and B. Anderton, Molecular pathology of Alzheimer's disease in sporadic and familial Alzheimer's disease with mutations in the amyloid precursor protein, Biochemical Society Transactions, vol.20, issue.3, pp.642-645, 1992.
DOI : 10.1042/bst0200642

N. Sergeant, J. David, D. Lefranc, P. Vermersch, A. Wattez et al., Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases, FEBS Letters, vol.26, issue.3, pp.578-582, 1997.
DOI : 10.1016/S0014-5793(97)00859-4

M. Goedert, M. Spillantini, N. Cairns, and R. Crowther, Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms, Neuron, vol.8, issue.1, pp.159-168, 1992.
DOI : 10.1016/0896-6273(92)90117-V

N. Sergeant, A. Wattez, and A. Delacourte, Neurofibrillary Degeneration in Progressive Supranuclear Palsy andCorticobasal Degeneration. Tau Pathologies with Exclusively "Exon10" Isoforms, Journal of Neurochemistry, vol.72, issue.3, pp.1243-1249, 1999.
DOI : 10.1046/j.1471-4159.1999.0721243.x

M. Tolnay, N. Sergeant, A. Ghestem, S. Chalbot, D. Vos et al., Argyrophilic grain disease and Alzheimer s disease are ' distinguished by their different distribution of tau protein isoforms, Acta neuropathologica, vol.104, issue.4, pp.425-434, 2002.

N. Cairns, E. Bigio, I. Mackenzie, M. Neumann, V. Lee et al., Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration, Acta Neuropathologica, vol.51, issue.Suppl 1, pp.5-22, 2007.
DOI : 10.1007/s00401-007-0237-2

C. Hickey, T. Chisholm, M. Passmore, O. Brien-'jd, and J. Johnston, Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies, Current Alzheimer Research, vol.5, issue.1, pp.52-60, 2008.
DOI : 10.2174/156720508783884657

K. Buerger, R. Zinkowski, S. Teipel, H. Arai, J. Debernardis et al., Differentiation of geriatric major depression from Alzheimer s disease with CSF tau protein phosphorylated at threonine 231 ' . The American journal of psychiatry, pp.376-379, 2003.

K. Blennow, Cerebrospinal fluid protein biomarkers for Alzheimer???s disease, NeuroRX, vol.12, issue.Suppl 179, pp.213-225, 2004.
DOI : 10.1602/neurorx.1.2.213

K. Blennow and E. Vanmechelen, CSF markers for pathogenic processes in Alzheimer s disease: diagnostic implications and use in clinical neurochemistry ' . Brain research bulletin, pp.235-242, 2003.

M. Sjogren, H. Vanderstichele, H. Agren, O. Zachrisson, M. Edsbagge et al., Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values, Clinical chemistry, vol.47, issue.10, pp.1776-1781, 2001.

C. Clark, S. Xie, J. Chittams, D. Ewbank, E. Peskind et al., Cerebrospinal Fluid Tau and ??-Amyloid, Archives of Neurology, vol.60, issue.12, pp.1696-1702, 2003.
DOI : 10.1001/archneur.60.12.1696

P. Sanchez-juan, A. Green, A. Ladogana, N. Cuadrado-corrales, R. Saanchez-valle et al., CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease, Neurology, vol.67, issue.4, pp.637-643, 2006.
DOI : 10.1212/01.wnl.0000230159.67128.00

C. Goodall, M. Head, D. Everington, J. Ironside, R. Knight et al., Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.1, pp.89-91, 2006.
DOI : 10.1136/jnnp.2005.065755

I. Medana, R. Lindert, U. Wurster, T. Hien, N. Day et al., Cerebrospinal fluid levels of markers of brain parenchymal damage in Vietnamese adults with severe malaria, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.99, issue.8, pp.610-617, 2005.
DOI : 10.1016/j.trstmh.2004.11.017

S. Matsushita, T. Miyakawa, H. Maesato, T. Matsui, A. Yokoyama et al., Elevated cerebrospinal fluid tau protein levels in Wernicke s ' encephalopathy . Alcoholism, clinical and experimental research, pp.1091-1095, 2008.

J. De-bont, H. Vanderstichele, R. Reddingius, R. Pieters, and S. Van-gool, Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients, European Journal of Paediatric Neurology, vol.12, issue.4, pp.334-341, 2008.
DOI : 10.1016/j.ejpn.2007.09.007

H. Bian, J. Van-swieten, S. Leight, L. Massimo, E. Wood et al., CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, vol.70, issue.Issue 19, Part 2, pp.1827-1835, 2008.
DOI : 10.1212/01.wnl.0000311445.21321.fc

M. Grossman, J. Farmer, S. Leight, M. Work, P. Moore et al., Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Annals of Neurology, vol.160, issue.5, pp.721-729, 2005.
DOI : 10.1002/ana.20477

Y. Pijnenburg, N. Schoonenboom, S. Rosso, C. Mulder, V. Kamp et al., CSF tau and A??42 are not useful in the diagnosis of frontotemporal lobar degeneration, Neurology, vol.62, issue.9, p.1649, 2004.
DOI : 10.1212/01.WNL.0000123014.03499.A7

B. Mollenhauer, L. Cepek, M. Bibl, J. Wiltfang, W. Schulz-schaeffer et al., Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies . Dementia and geriatric cognitive disorders, pp.164-170, 2005.

M. Bibl, B. Mollenhauer, H. Esselmann, P. Lewczuk, C. Trenkwalder et al., CSF diagnosis of Alzheimer???s disease and dementia with Lewy bodies, Journal of Neural Transmission, vol.313, issue.11, pp.1771-1778, 2006.
DOI : 10.1007/s00702-006-0537-z

H. Tschampa, W. Schulz-schaeffer, J. Wiltfang, S. Poser, M. Otto et al., Decreased CSF amyloid ??42 and normal tau levels in dementia with Lewy bodies, Neurology, vol.56, issue.4, p.576, 2001.
DOI : 10.1212/WNL.56.4.576

B. Mollenhauer, C. Trenkwalder, N. Von-ahsen, M. Bibl, P. Steinacker et al., Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson s disease dementia ' . Dementia and geriatric cognitive disorders, pp.200-208, 2006.

B. Borroni, F. Gardoni, L. Parnetti, L. Magno, M. Malinverno et al., Pattern of Tau forms in CSF is altered in progressive supranuclear palsy, Neurobiology of Aging, vol.30, issue.1, 2007.
DOI : 10.1016/j.neurobiolaging.2007.05.009

J. Brettschneider, A. Petzold, S. Sussmuth, A. Ludolph, and H. Tumani, Axonal damage markers in cerebrospinal fluid are increased in ALS, Neurology, vol.66, issue.6, pp.852-856, 2006.
DOI : 10.1212/01.wnl.0000203120.85850.54

F. Jimenez-jimenez, A. Hernanz, S. Medina-acebron, F. De-bustos, J. Zurdo et al., Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis, Acta Neurologica Scandinavica, vol.47, issue.5, pp.114-117, 2005.
DOI : 10.1016/S0896-6273(00)81127-7

M. Boban, K. Grbic, M. Mladinov, P. Hof, C. Sussmair et al., Cerebrospinal fluid markers in differential diagnosis of Alzheimer s disease and vascular dementia, Collegium antropologicum, vol.32, pp.31-36, 2008.

K. Hein-nee-maier, A. Kohler, R. Diem, M. Sattler, I. Demmer et al., Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis, Neuroscience Letters, vol.436, issue.1, pp.72-76, 2008.
DOI : 10.1016/j.neulet.2008.02.064

J. Brettschneider, M. Maier, S. Arda, C. A. Sussmuth, S. Kassubek et al., Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis, Multiple Sclerosis, vol.11, issue.3, pp.261-265, 2005.
DOI : 10.1191/1352458505ms1159oa

K. Blennow, CSF biomarkers for Alzheimer s disease: use in early diagnosis and evaluation of drug treatment ' . Expert review of molecular diagnostics, pp.661-672, 2005.

H. Hampel, K. Buerger, R. Zinkowski, S. Teipel, A. Goernitz et al., Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study . Archives of general psychiatry, pp.95-102, 2004.

M. Riemenschneider, S. Wagenpfeil, H. Vanderstichele, M. Otto, J. Wiltfang et al., Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt???Jakob disease from other dementias, Molecular Psychiatry, vol.8, issue.3, pp.343-347, 2003.
DOI : 10.1038/sj.mp.4001220

M. Sjogren, P. Davidsson, A. Wallin, A. Granerus, E. Grundstrom et al., Decreased CSF-beta-amyloid 42 in Alzheimer s disease ' and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms . Dementia and geriatric cognitive disorders, pp.112-118, 2002.

K. Buerger, R. Zinkowski, S. Teipel, T. Tapiola, H. Arai et al., Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231, Archives of Neurology, vol.59, issue.8, pp.1267-1272, 2002.
DOI : 10.1001/archneur.59.8.1267

H. Vanderstichele, D. Vreese, K. Blennow, K. Andreasen, N. Sindic et al., Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer s disease and dementia with Lewy bodies, Clin Chem Lab Med, vol.44, issue.12, pp.1472-1480, 2006.

M. Verbeek, Y. Pijnenburg, N. Schoonenboom, B. Kremer, and P. Scheltens, Cerebrospinal fluid tau levels in frontotemporal dementia, Annals of Neurology, vol.51, issue.4, pp.656-657, 2005.
DOI : 10.1002/ana.20642

P. Lewczuk, H. Esselmann, M. Otto, J. Maler, A. Henkel et al., Neurochemical diagnosis of Alzheimer???s dementia by CSF A??42, A??42/A??40 ratio and total tau, Neurobiology of Aging, vol.25, issue.3, pp.273-281, 2004.
DOI : 10.1016/S0197-4580(03)00086-1

E. Huey, N. Mirza, K. Putnam, H. Soares, G. Csako et al., Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients . Dementia and geriatric cognitive disorders, pp.48-53, 2006.

M. Blomqvist, C. Reynolds, H. Katzov, L. Feuk, N. Andreasen et al., Towards compendia of negative genetic association studies: an example for Alzheimer disease, Human Genetics, vol.8, issue.Database issue, pp.29-37, 2006.
DOI : 10.1007/s00439-005-0078-9

J. Kauwe, C. Cruchaga, K. Mayo, C. Fenoglio, S. Bertelsen et al., Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition, Proceedings of the National Academy of Sciences, vol.105, issue.23, pp.8050-8054, 2008.
DOI : 10.1073/pnas.0801227105

S. Laws, P. Friedrich, J. Diehl-schmid, J. Muller, T. Eisele et al., Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer s disease ' . Molecular psychiatry, pp.510-517, 2007.

C. Dhaenens, E. Van-brussel, S. Schraen-maschke, F. Pasquier, A. Delacourte et al., Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer s disease ' . Neuroscience letters, pp.290-292, 2004.

M. Andersson, A. Sjolander, N. Andreasen, L. Minthon, O. Hansson et al., Kinesin gene variability may affect tau phosphorylation in early Alzheimer s disease ', International journal of molecular medicine, vol.20, issue.2, pp.233-239, 2007.

B. Dubois, H. Feldman, C. Jacova, S. Dekosky, P. Barberger-gateau et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-746, 2007.
DOI : 10.1016/S1474-4422(07)70178-3

N. Andreasen and K. Blennow, CSF biomarkers for mild cognitive impairment and early Alzheimer's disease, Clinical Neurology and Neurosurgery, vol.107, issue.3, pp.165-173, 2005.
DOI : 10.1016/j.clineuro.2004.10.011

N. Andreasen, E. Vanmechelen, H. Vanderstichele, P. Davidsson, and K. Blennow, Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer s disease in patients with mild cognitive impairment, Acta Neurol Scand, vol.179, pp.47-51, 2003.

M. Ewers, K. Buerger, S. Teipel, P. Scheltens, J. Schroder et al., Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI, Neurology, vol.69, issue.24, pp.2205-2212, 2007.
DOI : 10.1212/01.wnl.0000286944.22262.ff

K. Buerger, S. Teipel, R. Zinkowski, K. Blennow, H. Arai et al., CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects, Neurology, vol.59, issue.4, pp.627-629, 2002.
DOI : 10.1212/WNL.59.4.627

M. De-leon, S. Desanti, R. Zinkowski, P. Mehta, D. Pratico et al., Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment, Neurobiology of Aging, vol.27, issue.3, pp.394-401, 2006.
DOI : 10.1016/j.neurobiolaging.2005.07.003

O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow et al., Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, The Lancet Neurology, vol.5, issue.3, pp.228-234, 2006.
DOI : 10.1016/S1474-4422(06)70355-6

S. Herukka, M. Hallikainen, H. Soininen, and T. Pirttila, CSF A??42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment, Neurology, vol.64, issue.7, pp.1294-1297, 2005.
DOI : 10.1212/01.WNL.0000156914.16988.56

S. Herukka, S. Helisalmi, M. Hallikainen, S. Tervo, H. Soininen et al., CSF A??42, Tau and phosphorylated Tau, APOE ??4 allele and MCI type in progressive MCI, Neurobiology of Aging, vol.28, issue.4, pp.507-514, 2007.
DOI : 10.1016/j.neurobiolaging.2006.02.001

M. Brys, E. Pirraglia, K. Rich, S. Rolstad, L. Mosconi et al., Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment, Neurobiology of Aging, vol.30, issue.5, 2007.
DOI : 10.1016/j.neurobiolaging.2007.08.010

C. Decarli, Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, The Lancet Neurology, vol.2, issue.1, pp.15-21, 2003.
DOI : 10.1016/S1474-4422(03)00262-X

J. Ringman, S. Younkin, D. Pratico, W. Seltzer, G. Cole et al., Biochemical markers in persons with preclinical familial Alzheimer disease, Neurology, vol.71, issue.2, 2008.
DOI : 10.1212/01.wnl.0000303973.71803.81

A. Martinez-yelamos, A. Saiz, J. Bas, J. Hernandez, F. Graus et al., Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis, Neuroscience Letters, vol.363, issue.1, pp.14-17, 2004.
DOI : 10.1016/j.neulet.2004.03.039

K. Jin, A. Takeda, Y. Shiga, S. Sato, A. Ohnuma et al., CSF tau protein: A new prognostic marker for Guillain-Barre syndrome, Neurology, vol.67, issue.8, pp.1470-1472, 2006.
DOI : 10.1212/01.wnl.0000240119.29939.c7

M. Ost, K. Nylen, L. Csajbok, A. Ohrfelt, M. Tullberg et al., Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury, Neurology, vol.67, issue.9, pp.1600-1604, 2006.
DOI : 10.1212/01.wnl.0000242732.06714.0f

H. Zetterberg, M. Pedersen, K. Lind, M. Svensson, S. Rolstad et al., Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years, Journal of Alzheimer's Disease, vol.12, issue.3, pp.255-260, 2007.
DOI : 10.3233/JAD-2007-12307

K. Blennow and H. Hampel, CSF markers for incipient Alzheimer's disease, The Lancet Neurology, vol.2, issue.10, pp.605-613, 2003.
DOI : 10.1016/S1474-4422(03)00530-1

H. Hampel, A. Mitchell, K. Blennow, R. Frank, S. Brettschneider et al., Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activity, Journal of Neural Transmission, vol.111, issue.3, pp.247-272, 2004.
DOI : 10.1007/s00702-003-0065-z

J. Wiltfang, P. Lewczuk, P. Riederer, E. Grunblatt, C. Hock et al., Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia, The World Journal of Biological Psychiatry, vol.70, issue.2, pp.69-84, 2005.
DOI : 10.1080/01688638608405173

S. Engelborghs, D. Vreese, K. Van-de-casteele, T. Vanderstichele, H. Van-everbroeck et al., Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiology of Aging, vol.29, issue.8, pp.1143-1159, 2008.
DOI : 10.1016/j.neurobiolaging.2007.02.016

F. Bouwman, W. Van-der-flier, N. Schoonenboom, E. Van-elk, A. Kok et al., Longitudinal changes of CSF biomarkers in memory clinic patients, Neurology, vol.69, issue.10, pp.1006-1011, 2007.
DOI : 10.1212/01.wnl.0000271375.37131.04

J. Bahl, N. Heegaard, G. Falkenhorst, H. Laursen, H. Hogenhaven et al., The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer s disease, Neurobiology of aging, 2008.

B. Van-everbroeck, J. Boons, and P. Cras, Cerebrospinal fluid biomarkers in Creutzfeldt???Jakob disease, Clinical Neurology and Neurosurgery, vol.107, issue.5, pp.355-360, 2005.
DOI : 10.1016/j.clineuro.2004.12.002

A. Atkinson, Biomarkers and surrogate endpoints: preferred definitions and conceptual framework *, Clin Pharmacol Ther, vol.69, pp.89-95, 2001.

R. Rouzier, R. Rajan, P. Wagner, K. Hess, D. Gold et al., Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer, Proceedings of the National Academy of Sciences, vol.102, issue.23, pp.8315-8320, 2005.
DOI : 10.1073/pnas.0408974102

B. Zhang, M. Higuchi, Y. Yoshiyama, T. Ishihara, M. Forman et al., Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy, Journal of Neuroscience, vol.24, issue.19, pp.4657-4667, 2004.
DOI : 10.1523/JNEUROSCI.0797-04.2004

F. Zemlan, J. Mulchahey, and G. Gudelsky, Quantification and localization of kainic acid-induced neurotoxicity employing a new biomarker of cell death: cleaved microtubule-associated protein-tau (c-tau), Neuroscience, vol.121, issue.2, pp.399-409, 2003.
DOI : 10.1016/S0306-4522(03)00459-7

E. Portelius, S. Hansson, A. Tran, H. Zetterberg, P. Grognet et al., Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry, Journal of Proteome Research, vol.7, issue.5, pp.2114-2120, 2008.
DOI : 10.1021/pr7008669

M. Vestergaard, K. Kerman, D. Kim, M. Ha, and E. Tamiya, Detection of Alzheimer's tau protein using localised surface plasmon resonance-based immunochip, Talanta, vol.74, issue.4, pp.1038-1042, 2008.
DOI : 10.1016/j.talanta.2007.06.009

D. States, G. Omenn, T. Blackwell, D. Fermin, J. Eng et al., Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study, Nature Biotechnology, vol.14, issue.3, pp.333-338, 2006.
DOI : 10.1038/nbt1183

A. Bitsch, C. Horn, Y. Kemmling, M. Seipelt, U. Hellenbrand et al., Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke, European Neurology, vol.47, issue.1, pp.45-51, 2002.
DOI : 10.1159/000047946

M. Wunderlich, H. Lins, M. Skalej, C. Wallesch, and M. Goertler, Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke, Clinical Neurology and Neurosurgery, vol.108, issue.6, pp.558-563, 2006.
DOI : 10.1016/j.clineuro.2005.12.006

G. Shaw, E. Jauch, and F. Zemlan, Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury . Annals of emergency medicine, pp.254-257, 2002.

F. Zemlan, E. Jauch, J. Mulchahey, S. Gabbita, W. Rosenberg et al., C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome, Brain Research, vol.947, issue.1, pp.131-139, 2002.
DOI : 10.1016/S0006-8993(02)02920-7

D. Chatfield, F. Zemlan, D. Day, and D. Menon, Discordant temporal patterns of S100 ?? and cleaved tau protein elevation after head injury: a pilot study, British Journal of Neurosurgery, vol.16, issue.5, pp.471-476, 2002.
DOI : 10.1080/0268869021000030285

Y. Hu, S. He, X. Wang, Q. Duan, I. Grundke-iqbal et al., Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer s ' disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay . The American journal of pathology, pp.1269-1278, 2002.

M. Kanai, E. Matsubara, K. Isoe, K. Urakami, K. Nakashima et al., Longitudinal study of cerebrospinal fluid levels of tau, A?1-40, and A?1-42(43) in Alzheimer's disease: A study in Japan, Annals of Neurology, vol.37, issue.1, pp.17-26, 1998.
DOI : 10.1002/ana.410440108

N. Andreasen, L. Minthon, A. Clarberg, P. Davidsson, J. Gottfries et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, Neurology, vol.53, issue.7, pp.1488-1494, 1999.
DOI : 10.1212/WNL.53.7.1488

T. Sunderland, B. Wolozin, D. Galasko, J. Levy, R. Dukoff et al., Longitudinal stability of CSF tau levels in Alzheimer patients, Biological Psychiatry, vol.46, issue.6, pp.750-755, 1999.
DOI : 10.1016/S0006-3223(99)00143-2

P. Sanchez-juan, R. Sanchez-valle, A. Green, A. Ladogana, N. Cuadrado-corrales et al., Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis, Journal of Neurology, vol.55, issue.7, pp.901-906, 2007.
DOI : 10.1007/s00415-006-0472-9

C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele et al., Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neuroscience Letters, vol.297, issue.3, pp.187-190, 2001.
DOI : 10.1016/S0304-3940(00)01697-9

S. Van-gool, E. Van-kerschaver, P. Brock, H. Pottel, F. Hulstaert et al., Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies, Leukemia, vol.14, issue.12, pp.2076-2084, 2000.
DOI : 10.1038/sj.leu.2401934

L. Parnetti, S. Amici, A. Lanari, C. Romani, C. Antognelli et al., Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors, Neurological Sciences, vol.23, issue.0, pp.95-96, 2002.
DOI : 10.1007/s100720200086

M. Degerman-gunnarsson, L. Kilander, H. Basun, and L. Lannfelt, Reduction of phosphorylated tau during memantine treatment of Alzheimer s disease ' . Dementia and geriatric cognitive disorders, pp.247-252, 2007.

S. Gilman, M. Koller, R. Black, L. Jenkins, S. Griffith et al., Clinical effects of A?? immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, issue.9, pp.1553-1562, 2005.
DOI : 10.1212/01.WNL.0000159740.16984.3C

R. Riekse, G. Li, E. Petrie, J. Leverenz, D. Vavrek et al., Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid, Journal of Alzheimer's Disease, vol.10, issue.4, pp.399-406, 2006.
DOI : 10.3233/JAD-2006-10408

B. Borroni, D. Yancopoulou, M. Tsutsui, A. Padovani, S. Sawcer et al., Association Between Tau H2 Haplotype and Age at Onset in Frontotemporal Dementia, Archives of Neurology, vol.62, issue.9, pp.1419-1422, 2005.
DOI : 10.1001/archneur.62.9.1419

B. Zhang, A. Maiti, S. Shively, F. Lakhani, G. Mcdonald-jones et al., Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model, Proceedings of the National Academy of Sciences, vol.102, issue.1, pp.227-231, 2005.
DOI : 10.1073/pnas.0406361102